Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

C. Krieckaert; B. Hernandez-Breijo; J.E. Gehin; G. le Meledo; A. Balsa; M. Jani; D. Mulleman; V. Navarro-Compan; G. Wolbink; J. Isaac; A. van Tubergen

doi:10.1136/rmdopen-2022-002216

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

C. Krieckaert, B. Hernandez-Breijo, J.E. Gehin, G. le Meledo, A. Balsa, M. Jani, D. Mulleman, V. Navarro-Compan, G. Wolbink, J. Isaac, A. van Tubergen^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Original language	English
Article number	e002216
Number of pages	13
Journal	RMD Open
Volume	8
Issue number	2
DOIs	https://doi.org/10.1136/rmdopen-2022-002216
Publication status	Published - 1 Jun 2022

Keywords

Arthritis
Psoriatic
Rheumatoid
Biological Therapy
Pharmacokinetics
Spondylitis
Ankylosing
ANTI-ADALIMUMAB ANTIBODIES
LONG-TERM TREATMENT
SERUM INFLIXIMAB CONCENTRATIONS
SUCCESSFUL DOSE REDUCTION
CLINICAL-RESPONSE
ANKYLOSING-SPONDYLITIS
TROUGH LEVELS
PSORIATIC-ARTHRITIS
OPEN-LABEL
DOUBLE-BLIND

Access to Document

10.1136/rmdopen-2022-002216Licence: CC BY-NC

Cite this

Krieckaert, C., Hernandez-Breijo, B., Gehin, J. E., le Meledo, G., Balsa, A., Jani, M., Mulleman, D., Navarro-Compan, V., Wolbink, G., Isaac, J., & van Tubergen, A. (2022). Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open, 8(2), [e002216]. https://doi.org/10.1136/rmdopen-2022-002216

Krieckaert, C. ; Hernandez-Breijo, B. ; Gehin, J.E. ; le Meledo, G. ; Balsa, A. ; Jani, M. ; Mulleman, D. ; Navarro-Compan, V. ; Wolbink, G. ; Isaac, J. ; van Tubergen, A. / Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. In: RMD Open. 2022 ; Vol. 8, No. 2.

@article{e4367693231b47e0aa7bfad049eb51b9,

title = "Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider",

keywords = "Arthritis, Psoriatic, Rheumatoid, Biological Therapy, Pharmacokinetics, Spondylitis, Ankylosing, ANTI-ADALIMUMAB ANTIBODIES, LONG-TERM TREATMENT, SERUM INFLIXIMAB CONCENTRATIONS, SUCCESSFUL DOSE REDUCTION, CLINICAL-RESPONSE, ANKYLOSING-SPONDYLITIS, TROUGH LEVELS, PSORIATIC-ARTHRITIS, OPEN-LABEL, DOUBLE-BLIND",

author = "C. Krieckaert and B. Hernandez-Breijo and J.E. Gehin and {le Meledo}, G. and A. Balsa and M. Jani and D. Mulleman and V. Navarro-Compan and G. Wolbink and J. Isaac and {van Tubergen}, A.",

year = "2022",

month = jun,

day = "1",

doi = "10.1136/rmdopen-2022-002216",

language = "English",

volume = "8",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "2",

}

Krieckaert, C, Hernandez-Breijo, B, Gehin, JE, le Meledo, G, Balsa, A, Jani, M, Mulleman, D, Navarro-Compan, V, Wolbink, G, Isaac, J & van Tubergen, A 2022, 'Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider', RMD Open, vol. 8, no. 2, e002216. https://doi.org/10.1136/rmdopen-2022-002216

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. / Krieckaert, C.; Hernandez-Breijo, B.; Gehin, J.E.; le Meledo, G.; Balsa, A.; Jani, M.; Mulleman, D.; Navarro-Compan, V.; Wolbink, G.; Isaac, J.; van Tubergen, A.

In: RMD Open, Vol. 8, No. 2, e002216, 01.06.2022.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

AU - Krieckaert, C.

AU - Hernandez-Breijo, B.

AU - Gehin, J.E.

AU - le Meledo, G.

AU - Balsa, A.

AU - Jani, M.

AU - Mulleman, D.

AU - Navarro-Compan, V.

AU - Wolbink, G.

AU - Isaac, J.

AU - van Tubergen, A.

PY - 2022/6/1

Y1 - 2022/6/1

KW - Arthritis

KW - Psoriatic

KW - Rheumatoid

KW - Biological Therapy

KW - Pharmacokinetics

KW - Spondylitis

KW - Ankylosing

KW - ANTI-ADALIMUMAB ANTIBODIES

KW - LONG-TERM TREATMENT

KW - SERUM INFLIXIMAB CONCENTRATIONS

KW - SUCCESSFUL DOSE REDUCTION

KW - CLINICAL-RESPONSE

KW - ANKYLOSING-SPONDYLITIS

KW - TROUGH LEVELS

KW - PSORIATIC-ARTHRITIS

KW - OPEN-LABEL

KW - DOUBLE-BLIND

U2 - 10.1136/rmdopen-2022-002216

DO - 10.1136/rmdopen-2022-002216

M3 - Review article

VL - 8

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 2

M1 - e002216

ER -